Jiangsu, China

Shangshu Pan

This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Amphastar Nanjing Pharmaceuticals Inc.. Active years: 2020-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shangshu Pan. Retrieved from https://idiyas.com/inventor/shangshu-pan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.5

ph-index = 1


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Shangshu Pan in Biopharmaceuticals

Introduction

Shangshu Pan is a notable inventor based in Jiangsu, China, recognized for his contributions to the field of biopharmaceuticals. He has been instrumental in developing innovative methods for preparing insulin and liraglutide intermediate polypeptides. With a total of 2 patents to his name, his work has significantly impacted the pharmaceutical industry.

Latest Patents

Shangshu Pan's latest patents include a novel pro-insulin aspart structure and a method for preparing insulin aspart. This invention provides a unique design for pro-insulin aspart and outlines a method that involves constructing recombinant insulin aspart engineered bacteria. The process includes inducing the expression of an insulin fusion protein as an inclusion body and extracting it through various purification operations. By modifying the recombinant leading peptide and C-peptide sequences, the method eliminates the need for a cyanogen bromide cleavage step, enhancing the overall efficiency of the process.

Another significant patent is the method for preparing a liraglutide intermediate polypeptide, specifically GLP-1 (7-37). This preparation method involves constructing recombinant liraglutide engineered bacteria to induce the expression of a liraglutide intermediate fusion protein. The process includes denaturation, renaturation, enzyme digestion, separation, and purification, resulting in a product with a purity of over 87% and a yield exceeding 85%. This innovative approach alters the expression pattern to increase the expression level significantly.

Career Highlights

Shangshu Pan is currently employed at Amphastar Nanjing Pharmaceuticals Inc., where he continues to advance his research in biopharmaceuticals. His work has been pivotal in developing new methods that enhance the production and quality of important therapeutic proteins.

Collaborations

Shangshu Pan has collaborated with notable colleagues, including Chuangen Tang and Xiaorui Liu, contributing to the advancement of their shared research goals.

Conclusion

Shangshu Pan's innovative work in the field of biopharmaceuticals, particularly in the preparation of insulin and liraglutide polypeptides, showcases his significant contributions to the industry. His patents reflect a commitment to improving biopharmaceutical processes, ultimately benefiting patients and the healthcare sector.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…